Confirmatory detection of neutralizing antibodies to AAV gene therapy using a cell-based transduction inhibition assay

por Kasprzyk, Theresa, Triffault, Sabrina, Long, Brian R., Zoog, Stephen J., Vettermann, Christian
Publicado 2022

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

por Cheung, Ruby, deHart, Gregory W., Jesaitis, Lynne, Zoog, Stephen J., Melton, Andrew C.
Publicado 2018

Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates

por Yang, Fan, Patton, Kathryn, Kasprzyk, Theresa, Long, Brian, Gupta, Soumi, Zoog, Stephen J., Tracy, Kristin, Vettermann, Christian
Publicado 2021

Strategy to detect pre-existing immunity to AAV gene therapy

por Falese, L, Sandza, K, Yates, B, Triffault, S, Gangar, S, Long, B, Tsuruda, L, Carter, B, Vettermann, C, Zoog, S J, Fong, S
Publicado 2017

Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method

por Patton, Kathryn S., Harrison, M. Travis, Long, Brian R., Lau, Kelly, Holcomb, Jennifer, Owen, Rachel, Kasprzyk, Theresa, Janetzki, Sylvia, Zoog, Stephen J., Vettermann, Christian
Publicado 2021

Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer

por Sandza, Krystal, Clark, Annie, Koziol, Elli, Akeefe, Hassibullah, Yang, Fan, Holcomb, Jennifer, Patton, Kathryn, Hammon, Kevin, Mitchell, Nina, Wong, Wing Y., Zoog, Stephen J., Kim, Benjamin, Henshaw, Joshua, Vettermann, Christian
Publicado 2021

Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A

por Long, Brian R., Veron, Philippe, Kuranda, Klaudia, Hardet, Romain, Mitchell, Nina, Hayes, Gregory M., Wong, Wing Yen, Lau, Kelly, Li, Mingjin, Hock, M. Benjamin, Zoog, Stephen J., Vettermann, Christian, Mingozzi, Federico, Schweighardt, Becky
Publicado 2021

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials

por Gupta, Soumi, Lau, Kelly, Harding, Cary O., Shepherd, Gillian, Boyer, Ryan, Atkinson, John P., Knight, Vijaya, Olbertz, Joy, Larimore, Kevin, Gu, Zhonghu, Li, Mingjin, Rosen, Orli, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky
Publicado 2018

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

por Qi, Yulan, Patel, Gina, Henshaw, Joshua, Gupta, Soumi, Olbertz, Joy, Larimore, Kevin, Harding, Cary O., Merilainen, Markus, Zori, Roberto, Longo, Nicola, Burton, Barbara K., Li, Mingjin, Gu, Zhonghua, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky
Publicado 2021